Combination therapies blocking CTLA-4 and PD-1 have been tested, and results have shown improved overall survival compared with monotherapy in patients with advanced melanoma 45 and metastatic renal cell carcinoma 46. This evidence concerns the gene CTLA4 and melanoma.